These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 30388256)

  • 41. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer.
    Myte R; Harlid S; Sundkvist A; Gylling B; Häggström J; Zingmark C; Burström AL; Palmqvist R; Guelpen BV
    Sci Rep; 2020 Mar; 10(1):5336. PubMed ID: 32210264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Jun; 38(6):842-9. PubMed ID: 17350669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Associations of red and processed meat intake with major molecular pathological features of colorectal cancer.
    Carr PR; Jansen L; Bienert S; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Eur J Epidemiol; 2017 May; 32(5):409-418. PubMed ID: 28646407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular Profiling Based on KRAS/BRAF Mutation, Methylation, and Microsatellite Statuses in Serrated Lesions.
    Sugai T; Eizuka M; Fujita Y; Kawasaki K; Yamamoto E; Ishida K; Yamano H; Suzuki H; Matsumoto T
    Dig Dis Sci; 2018 Oct; 63(10):2626-2638. PubMed ID: 29974407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status.
    Myte R; Gylling B; Häggström J; Schneede J; Löfgren-Burström A; Huyghe JR; Hallmans G; Meyer K; Johansson I; Ueland PM; Palmqvist R; Van Guelpen B
    PLoS One; 2018; 13(4):e0196233. PubMed ID: 29694444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular subtypes of colorectal cancers determined by PCR-based analysis.
    Sugai T; Eizuka M; Takahashi Y; Fukagawa T; Habano W; Yamamoto E; Akasaka R; Otuska K; Matsumoto T; Suzuki H
    Cancer Sci; 2017 Mar; 108(3):427-434. PubMed ID: 28083970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.
    Liu J; Tang L; Yi J; Li G; Lu Y; Xu Y; Zhao S; Mao R; Li X; Ren L; Wang K
    BMC Gastroenterol; 2019 Nov; 19(1):173. PubMed ID: 31690257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status.
    Myte R; Gylling B; Häggström J; Häggström C; Zingmark C; Löfgren Burström A; Palmqvist R; Van Guelpen B
    Int J Cancer; 2019 Jul; 145(2):327-337. PubMed ID: 30613980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tracking the molecular features of nonpolypoid colorectal neoplasms: a systematic review and meta-analysis.
    Voorham QJ; Rondagh EJ; Knol DL; van Engeland M; Carvalho B; Meijer GA; Sanduleanu S
    Am J Gastroenterol; 2013 Jul; 108(7):1042-56. PubMed ID: 23649184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):585-92. PubMed ID: 17239930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers.
    Drew DA; Nishihara R; Lochhead P; Kuchiba A; Qian ZR; Mima K; Nosho K; Wu K; Wang M; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    Am J Gastroenterol; 2017 Mar; 112(3):493-501. PubMed ID: 28117362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.